TLDR JAK inhibitors show promise in treating difficult skin diseases.
JAK inhibitors, a new class of anti-inflammatory medications targeting the JAK-STAT pathway, showed promise in treating chronic skin diseases that were historically resistant to treatment, such as vitiligo and alopecia areata. They also offered potential benefits for inadequately treated subtypes of atopic dermatitis and psoriasis, as well as genetic conditions like Darier's disease and Hailey-Hailey disease, and inflammatory conditions such as sarcoidosis and localized scleroderma. This review discussed JAK inhibitors approved for dermatologic use and highlighted promising early reports for additional conditions.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
295 citations
,
May 2016 in “Journal of the American Academy of Dermatology” Alopecia areata, a common autoimmune hair loss condition, often runs in families.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
